Insmed Incorporated (INSM) Stock Forecast
Data as of May 3, 2026Healthcare · Current price $133.75 (-1.89%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 20, 2026 | Tiago Fauth | Wells Fargo | $208.00 | +55.5% |
| Feb 19, 2026 | Graig Suvannavejh | Mizuho Securities | $211.00 | +57.8% |
| Jan 27, 2026 | Eliana Merle | Barclays | $231.00 | +72.7% |
| Jan 21, 2026 | Leonid Timashev | RBC Capital | $200.00 | +49.5% |
| Jan 12, 2026 | Danielle Brill | Truist Financial | $205.00 | +53.3% |
| Jan 8, 2026 | Maxwell Skor | Morgan Stanley | $157.00 | +17.4% |
| Dec 19, 2025 | Danielle Brill | Truist Financial | $202.00 | +51.0% |
| Dec 18, 2025 | Graig Suvannavejh | Mizuho Securities | $212.00 | +58.5% |
| Dec 18, 2025 | Leonid Timashev | RBC Capital | $195.00 | +45.8% |
| Dec 18, 2025 | Andy Chen | Wolfe Research | $167.00 | +24.9% |
| Dec 16, 2025 | Tiago Fauth | Wells Fargo | $234.00 | +75.0% |
| Dec 16, 2025 | Olivia Brayer | Cantor Fitzgerald | $230.00 | +72.0% |
| Dec 1, 2025 | Graig Suvannavejh | Mizuho Securities | $256.00 | +91.4% |
| Oct 31, 2025 | Leonid Timashev | RBC Capital | $215.00 | +60.7% |
| Oct 31, 2025 | Trung Huynh | UBS | $223.00 | +66.7% |
| Oct 29, 2025 | Graig Suvannavejh | Mizuho Securities | $196.00 | +46.5% |
| Oct 1, 2025 | Gavin Clark-Gartner | Evercore ISI | $180.00 | +34.6% |
| Aug 12, 2025 | Tiago Fauth | Wells Fargo | $140.00 | +4.7% |
| Aug 15, 2024 | Graig Suvannavejh | Mizuho Securities | $92.00 | -31.2% |
| Aug 9, 2024 | Tiago Fauth | Wells Fargo | $85.00 | -36.4% |
Top Analysts Covering INSM
INSM vs Sector & Market
| Metric | INSM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.04 | 2.24 | 2.41 |
| Analyst Count | 28 | 8 | 18 |
| Target Upside | +62.3% | +1150.2% | +14.9% |
| P/E Ratio | -22.58 | 6.89 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.56B | $1.71B | $1.80B | 15 |
| 2027-03-31 | $475M | $530M | $631M | 5 |
| 2027-06-30 | $541M | $605M | $720M | 6 |
| 2027-09-30 | $611M | $683M | $813M | 9 |
| 2027-12-31 | $656M | $733M | $872M | 5 |
| 2028-03-31 | $711M | $795M | $946M | 4 |
| 2028-06-30 | $757M | $847M | $1.01B | 6 |
| 2028-09-30 | $807M | $901M | $1.07B | 9 |
| 2028-12-31 | $854M | $955M | $1.14B | 4 |
| 2029-12-31 | $4.43B | $5.24B | $6.19B | 14 |
| 2030-12-31 | $5.50B | $6.51B | $7.69B | 8 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-4.27 | $-2.58 | $-1.27 | 15 |
| 2027-03-31 | $-0.23 | $-0.18 | $-0.16 | 4 |
| 2027-06-30 | $0.00 | $0.00 | $0.00 | 4 |
| 2027-09-30 | $0.18 | $0.21 | $0.26 | 4 |
| 2027-12-31 | $0.35 | $0.40 | $0.50 | 4 |
| 2028-03-31 | $0.19 | $0.22 | $0.28 | 5 |
| 2028-06-30 | $0.31 | $0.36 | $0.45 | 5 |
| 2028-09-30 | $0.43 | $0.50 | $0.62 | 5 |
| 2028-12-31 | $0.55 | $0.63 | $0.79 | 5 |
| 2029-12-31 | $6.67 | $8.35 | $10.32 | 14 |
| 2030-12-31 | $8.75 | $10.96 | $13.54 | 14 |
Frequently Asked Questions
What is the analyst consensus for INSM?
The consensus among 28 analysts covering Insmed Incorporated (INSM) is Buy with an average price target of $216.39.
What is the highest price target for INSM?
The highest price target for INSM is $256.00, set by Graig Suvannavejh at Mizuho Securities on 2025-12-01.
What is the lowest price target for INSM?
The lowest price target for INSM is $36.00, set by Graig Suvannavejh at Mizuho Securities on 2024-05-13.
How many analysts cover INSM?
28 analysts have issued ratings for Insmed Incorporated in the past 12 months.
Is INSM a buy or sell right now?
Based on 28 analyst ratings, INSM has a consensus rating of Buy (2.04/5) with a +62.3% upside to the consensus target of $216.39.
What are the earnings estimates for INSM?
Analysts estimate INSM will report EPS of $-2.58 for the period ending 2026-12-31, with revenue estimated at $1.71B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.